Sensei Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
FTH$12.68-42.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| September 30,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $19,131 | $13,011 |
| Marketable securities | 27,870 | 52,746 |
| Prepaid expenses | 1,016 | 1,168 |
| Other current assets | 81 | 325 |
| Total current assets | 48,098 | 67,250 |
| Right of use assets - operating leases, net | 3,206 | 4,330 |
| Right of use assets - financing leases, net | 964 | 1,543 |
| Property and equipment, net | 899 | 1,165 |
| Other non-current assets | 87 | 86 |
| Total assets | $53,254 | $74,374 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $1,676 | $1,694 |
| Compensation and employee benefits liabilities | 1,331 | 1,510 |
| Operating lease liabilities, current | 1,603 | 1,567 |
| Financing lease liabilities, current | 831 | 872 |
| Total current liabilities | 5,441 | 5,643 |
| Operating lease liabilities, non-current | 1,828 | 3,001 |
| Financing lease liabilities, non-current | 206 | 768 |
| Other non-current liabilities | — | 67 |
| Total liabilities | 7,475 | 9,479 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value and 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023; zero shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value and 250,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 25,151,379 and 25,030,188 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 3 | 3 |
| Additional paid-in capital | 300,044 | 296,996 |
| Accumulated deficit | (254,282) | (231,895) |
| Accumulated other comprehensive income (loss) | 14 | (209) |
| Total stockholders’ equity | 45,779 | 64,895 |
| Total liabilities and stockholders’ equity | $53,254 | $74,374 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.